---
schema_version: "secwatch.filing_event.v1"
accession: "0001326110-26-000025"
form_type: "8-K"
ticker: "IBRX"
cik: "0001326110"
company_name: "ImmunityBio, Inc."
filed_at: "2026-02-23T23:59:59+00:00"
generated_at: "2026-05-16T01:05:30.828610+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# ImmunityBio reports 700% YoY revenue growth to $113M; first lung cancer approval in Saudi Arabia

## Summary
- Full-year 2025 ANKTIVA net product revenue $113M (up ~700% YoY); Q4 net revenue $38.3M (up 431% YoY).
- Unit sales volume increased 750% in 2025 vs 2024; cash and securities $242.8M as of Dec 31, 2025.
- SFDA granted conditional accelerated approval for ANKTIVA + checkpoint inhibitors in metastatic NSCLC (Jan 2026) – first lung cancer approval globally.
- Global regulatory footprint expanded to 33 countries across 4 jurisdictions (US, UK, EU, Saudi Arabia) in under two years.
- Net loss attributable to common stockholders narrowed to $351.4M in 2025 from $413.6M in 2024.

## SEC filing metadata
- accession: 0001326110-26-000025
- form_type: 8-K
- ticker: IBRX
- cik: 0001326110
- company_name: ImmunityBio, Inc.
- filed_at: 2026-02-23T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1326110/000132611026000025/0001326110-26-000025-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1326110/000132611026000025/ibrx-20260223.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001326110-26-000025
- JSON: https://secwatch.observer/filing/0001326110-26-000025.json
- Plain text: https://secwatch.observer/filing/0001326110-26-000025.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.